Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation

  • Borrego, Belén
  • Alonso, Celia
  • Moreno, Sandra
  • de la Losa, Nuria
  • Sánchez-Cordón, Pedro J.
  • Brun Torres, Alejandro
17 Pág., Rift Valley fever (RVF) is an important zoonotic viral disease affecting several species of domestic and wild ruminants, causing major economic losses and dozens of human deaths in various geographical areas of Africa, where it is endemic. Although it is not present in Europe, there is a risk of its introduction and spread linked to globalisation and climate change. At present, the only measure that could help to prevent the disease is vaccination of flocks in areas at risk of RVF. Available live attenuated vaccines are an effective means of controlling the disease, but their use is often questioned due to residual virulence, particularly in susceptible hosts such as pregnant sheep. On the other hand, no vaccine is currently licensed for use in humans. The development of safe and effective vaccines is therefore a major area of research. In previous studies, we selected under selective mutagenic pressure a highly attenuated RVFV 56/74 virus variant called 40Fp8. This virus showed an extremely attenuated phenotype in both wild-type and immunodeficient A129 (IFNARKO) mice, yet was still able to induce protective immunity after a single inoculation, thus supporting its use as a safe, live attenuated vaccine. To further investigate its safety, in this work we have analysed the attenuation level of 40Fp8 in immunosuppressed mice (A129) when administered by the intranasal route, and compared it with other attenuated RVF viruses that are the basis of vaccines in use or in development. Our results show that 40Fp8 has a much higher attenuated level than these other viruses and confirm its potential as a candidate for safe RVF vaccine development., Work supported by grants AGL2017-83326-R funded by Ministerio de Ciencia e Innovacion MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” and PdC2021-121717-I00 funded by MCIN/AEI/10.13039/501100011033 and by the “European Union Next Generation EU/PRTR”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The 40Fp8 vaccine strain is safe and protects pregnant ewes from a virulent RVFV challenge

  • Borrego, Belén
  • Alonso, Celia
  • Moreno, Sandra
  • Calvo Pinilla, Eva María
  • Lorenzo, Gema
  • Sánchez-Cordón, Pedro J.
  • Brun Torres, Alejandro
In the present study, we evaluated the immunogenicity, safety and protective efficacy of the attenuated RVFV-40Fp8 strain in natural hosts (non-pregnant ewes) and in a highly susceptible host infection model such as pregnant ewes in the first third of pregnancy. Our results confirm the immunogenicity of 40Fp8 administration in non-pregnant and pregnant ewes, as well as the absence of foetal damage even after a high-dose vaccination regime in pregnant ewes. In addition, the ewes and their foetuses were protected against a virulent RVFV-56/74 strain challenge, as shown by comparative evaluation of blood, serum and different tissue samples from vaccinated and non-vaccinated pregnant ewes. These results confirm the potential use of 40Fp8 as a RVF live-attenuated vaccine candidate and pave the way for further clinical developments., This work was supported by grant AGL2017-83226-R and by grant PdC2021-121717-I00 funded by MCIN/AEI /10.13039/501100011033 and by European Union Next Generation EU/ PRTR., Peer reviewed